Trial Profile

A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Etoposide (Primary) ; Tivunatamig (Primary)
Indications Small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms Symbiotic-Lung-14
Sponsors Pfizer

Most Recent Events

28 Sep 2026 Planned End Date changed from 19 Mar 2031 to 24 Mar 2031.
28 Sep 2026 Planned primary completion date changed from 19 Mar 2028 to 24 Mar 2028.
28 Sep 2026 According to Pfizer media release, the data from the trial will be presented at the European Society for Medical Oncology (ESMO) Congress 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com